B and T cell responses to the 3rd and 4th dose of the BNT162b2 vaccine in dialysis patients

References

• Geetha D, Kronbichler A, Rutter M, Bajpai D, Menez S, Weissenbacher A, Anand S, Lin E, Carlson N, Sozio S, et al. Impact of the COVID-19 pandemic on the kidney community: lessons learned and future directions. Nat Rev Nephrol. 2022;18(11):724–7. doi:10.1038/s41581-022-00618-4.
   PubMed Web of Science ®Google Scholar
• Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis. 2021;77(2):190. doi:10.1053/J.AJKD.2020.09.003.
   PubMed Web of Science ®Google Scholar
• Taji L, Thomas D, Oliver MJ, Ip J, Tang Y, Yeung A, Cooper R, House AA, McFarlane P, Blake PG, et al. Covid-19 in patients undergoing long-term dialysis in Ontario. CMAJ. 2021;193(8):E278–E284. doi:10.1503/CMAJ.202601/TAB-RELATED-CONTENT.
   PubMed Web of Science ®Google Scholar
• Jager KJ, Kramer A, Chesnaye NC, Couchoud C, Sánchez-Álvarez JE, Garneata L, Collart F, Hemmelder MH, Ambühl P, Kerschbaum J, et al. Results from the ERA-EDTA registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98(6):1540–8. doi:10.1016/j.kint.2020.09.006.
   PubMed Web of Science ®Google Scholar
• Valeri AM, Robbins-Juarez SY, Stevens JS, Ahn W, Rao MK, Radhakrishnan J, Gharavi AG, Mohan S, Husain SA. Presentation and outcomes of patients with ESKD and COVID-19. J Am Soc Nephrol. 2020;31(7):1409–1415. doi:10.1681/ASN.2020040470/-/DCSUPPLEMENTAL.
   PubMed Web of Science ®Google Scholar
• Cancarevic I, Nassar M, Daoud A, Ali H, Nso N, Sanchez A, Parikh A, Ul Hosna A, Devanabanda B, Ahmed N, et al. Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: a systematic review and meta-analysis. World J Virol. 2022;11(5):352. doi:10.5501/WJV.V11.I5.352.
   PubMedGoogle Scholar
• Kato S, Chmielewski M, Honda H, Pecoits-Filho R, Matsuo S, Yuzawa Y, Tranaeus A, Stenvinkel P, Lindholm B. Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol. 2008;3(5):1526. doi:10.2215/CJN.00950208.
   PubMed Web of Science ®Google Scholar
• Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):8–15. doi:10.1053/J.ACKD.2019.01.004.
   PubMed Web of Science ®Google Scholar
• Ma BM, Yap DYH, Yip TPS, Hung IFN, Tang SCW, Chan TM. Vaccination in patients with chronic kidney disease—review of current recommendations and recent advances. Nephrology. 2021;26(1):5–11. doi:10.1111/NEP.13741.
   PubMed Web of Science ®Google Scholar
• Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81(4):495–501. doi:10.1007/S40265-021-01480-7.
   PubMed Web of Science ®Google Scholar
• Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–1423. doi:10.1056/NEJMOA2101765/SUPPL_FILE/NEJMOA2101765_DISCLOSURES.PDF.
   PubMed Web of Science ®Google Scholar
• Haas EJ, Angulo FJ, Mclaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819–29. doi:10.1016/S0140-6736(21)00947-8.
   PubMed Web of Science ®Google Scholar
• Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, Milo R, Alroy-Preis S, Ash N, Huppert A, et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385(24):e85. doi:10.1056/NEJMOA2114228.
   PubMed Web of Science ®Google Scholar
• Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, et al. Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 Months. N Engl J Med. 2021;385(24):e84. doi:10.1056/NEJMOA2114583.
   PubMed Web of Science ®Google Scholar
• Notarte KI, Guerrero-Arguero I, Velasco JV, Ver AT, Santos de Oliveira MH, Catahay JA, Khan MSR, Pastrana A, Juszczyk G, Torrelles JB, et al. Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: a systematic review. J Med Virol. 2022;94(7):2939. doi:10.1002/JMV.27688.
   PubMed Web of Science ®Google Scholar
• Stasi C, Meoni B, Voller F, Silvestri C. SARS-CoV-2 vaccination and the bridge between first and fourth dose: where are we? Vaccines. 2022;10(3):444. doi:10.3390/VACCINES10030444.
   Web of Science ®Google Scholar
• Glenn D, Hegde A, Kotzen E, EWK international. Systematic review of safety and efficacy of COVID-19 vaccines in patients with kidney disease. ncbi.nlm.nih.gov. 2021 undefined [accessed 2023 Feb 22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870446/.
   Google Scholar
• Falahi S, Sayyadi H, Kenarkoohi A. Immunogenicity of COVID-19 mRNA vaccines in hemodialysis patients: systematic review and meta-analysis. Heal Sci Rep. 2022;5(6):e874. doi:10.1002/HSR2.874.
   PubMedGoogle Scholar
• Sanders JSF, Bemelman FJ, Messchendorp AL, Baan CC, van Baarle D, van Binnendijk R, Diavatopoulos DA, Frölke SC, Geers D, GeurtsvanKessel CH, et al. The RECOVAC immune-response study: the immunogenicity, tolerability, and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant. Transplantation. 2022;106(4):821–34. doi:10.1097/TP.0000000000003983.
   PubMed Web of Science ®Google Scholar
• Sattler A, Schrezenmeier E, Weber UA, Potekhin A, Bachmann F, Straub-Hohenbleicher H, Budde K, Storz E, Proß V, Bergmann Y, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. J Clin Invest. 2021;131(14). doi:10.1172/JCI150175.
   Web of Science ®Google Scholar
• Strengert M, Becker M, Ramos GM, Dulovic A, Gruber J, Juengling J, Lürken K, Beigel A, Wrenger E, Lonnemann G, et al. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis. EBioMedicine. 2021;70:70. doi:10.1016/j.ebiom.2021.103524.
   Web of Science ®Google Scholar
• Rincon-Arevalo H, Choi M, Stefanski AL, Halleck F, Weber U, Szelinski F, Jahrsdörfer B, Schrezenmeier H, Ludwig C, Sattler A, et al. Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Sci Immunol. 2021;6(60):1031. doi:10.1126/SCIIMMUNOL.ABJ1031/SUPPL_FILE/SCIIMMUNOL.ABJ1031_TABLE_S1.ZIP.
   Web of Science ®Google Scholar
• Murt A, Dinc HO, Altiparmak MR, Yalin SF, Yadigar S, Parmaksiz E, Kocazeybek B, Pekpak M, Ataman MR. Waning of SARS-CoV-2 vaccine-induced immune response over 6 Months in peritoneal dialysis patients and the role of a booster dose in maintaining seropositivity. Nephron. 2022;146(6):559–563. doi:10.1159/000524658.
   PubMed Web of Science ®Google Scholar
• Azzolini E, Pozzi C, Germagnoli L, Oresta B, Carriglio N, Calleri M, Selmi C, De Santis M, Finazzi S, Carlo-Stella C, et al. mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Sci Alli. 2022;5(6):e202201381. doi:10.26508/LSA.202201381.
   PubMed Web of Science ®Google Scholar
• Anand S, Montez-Rath ME, Han J, Garcia P, Cadden L, Hunsader P, Morgan C, Kerschmann R, Beyer P, Dittrich M, et al. SARS-CoV-2 vaccine antibody response and breakthrough infection in patients receiving dialysis. Ann Intern Med. 2022;175(3):371–8. doi:10.7326/M21-4176.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhang H, Bao W, Fu S, Jin H. Immunogenicity rates after SARS-CoV-2 three-dose vaccination in patients under dialysis: a systematic review and meta-analysis. Vaccines. 2022;10(12):2070. doi:10.3390/vaccines10122070.
   Web of Science ®Google Scholar
• Notarte KI, Catahay JA, Peligro PJ, Velasco JV, Ver AT, Guerrero JJ, Liu J, Lippi G, Benoit SW, Henry BM, et al. Humoral response in hemodialysis patients post-SARS-CoV-2 mRNA vaccination: a systematic review of literature. Vaccines. 2023;11(4):724. doi:10.3390/VACCINES11040724.
   Web of Science ®Google Scholar
• Taheri S. Efficacy and safety of booster vaccination against SARS-CoV-2 in dialysis and renal transplant patients: systematic review and meta-analysis. Int Urol Nephrol. 2023;55(4):791–802. doi:10.1007/S11255-023-03471-X.
   PubMed Web of Science ®Google Scholar
• Edelstein M, Wiegler Beiruti K, Ben-Amram H, Bar-Zeev N, Sussan C, Asulin H, Strauss D, Bathish Y, Zarka S, Abu Jabal K. Antibody-mediated immunogenicity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following priming, boosting, and hybrid immunity: insights from 11 Months of follow-up of a healthcare worker cohort in Israel, December 2020–October 2021. Clin Infect Dis. 2022;75(1):E572–E578. doi:10.1093/CID/CIAC212.
   PubMedGoogle Scholar
• Notarte KI, Ver AT, Velasco JV, Pastrana A, Catahay JA, Salvagno GL, Yap EPH, Martinez-Sobrido LB, Torrelles J, Lippi G, et al. Effects of age, sex, serostatus, and underlying comorbidities on humoral response post-SARS-CoV-2 Pfizer-BioNTech mRNA vaccination: a systematic review. Crit Rev Clin Lab Sci. 2022;59(6):373–390. doi:10.1080/10408363.2022.2038539.
   PubMed Web of Science ®Google Scholar
• Jabal KA, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S, Edelstein M. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Euro Surveill. 2021;26(6). doi:10.2807/1560-7917.ES.2021.26.6.2100096.
   PubMedGoogle Scholar
• Berar-Yanay N, Freiman S, Shapira M, Saffoury A, Elemy A, Hamze M, Elhaj M, Zaher M, Matanis L, Armaly ZA, et al. Waning humoral response 3 to 6 Months after vaccination with the SARS-COV-2 BNT162b2 mRNA vaccine in dialysis patients. J Clin Med. 2022;11(1):64. doi:10.3390/JCM11010064.
   Web of Science ®Google Scholar
• Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24(8):1445–52. doi:10.1007/S00467-008-1046-0.
   PubMed Web of Science ®Google Scholar
• Madelon N, Lauper K, Breville G, Sabater Royo I, Goldstein R, Andrey DO, Grifoni A, Sette A, Kaiser L, Siegrist CA, et al. Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2022;75(1):E1037–E1045. doi:10.1093/CID/CIAB954.
   PubMed Web of Science ®Google Scholar